Musk’s Retort to Allegations
Elon Musk, the founder of Tesla, responded via social media to a Wall Street Journal report that alleged concerns among board members over his purported drug use.
In a post on his platform, X, Musk seemingly criticized the WSJ’s editorial standards by comparing them unfavorably to TMZ, a gossip-focused website.
Challenges to WSJ’s Claims
Musk’s attorney, Alex Spiro, refuted the claims made in the article, asserting that Musk undergoes regular and random drug testing at SpaceX without any failures.
The report suggested that Musk’s drug preference includes ketamine, with instances of LSD, cocaine, ecstasy, and psychedelic mushrooms allegedly used at exclusive private gatherings globally.
Concerns Surrounding Musk’s Behavior
According to the WSJ report, witnesses mentioned Musk’s use of various drugs at private events, with concerns raised by those close to him about potential health crises or business disruptions.
Concerns over drug use within SpaceX, an approved NASA transporter, raised federal policy violation concerns, which could jeopardize lucrative government contracts.
Implications on Business and Leadership
Musk’s alleged drug use and its impact on his behavior reportedly led to resignations within his companies, with specific instances cited, such as Linda Johnson Rice’s decision not to seek re-election to Tesla’s board due to purported frustration over Musk’s behavior.
Public and Legal Fallout
The report also detailed instances of Musk’s behavior during a SpaceX meeting in 2017, where concerns about his speech and behavior surfaced among executives.
Recent legal issues have emerged, including a complaint against SpaceX for alleged unfair labor practices, stemming from the termination of employees involved in an open letter critical of Musk’s behavior on social media.
Breaking News